Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

Judith E. Karp, Jeffrey E. Lancet

Research output: Contribution to journalReview articlepeer-review

Abstract

Farnesyltransferase inhibitors (FTIs) represent a new class of signal transduction inhibitors that block the processing of cellular polypeptides that have cysteine terminal residues and, by so doing, interdict multiple pathways involved in proliferation and survival of diverse malignant cell types. Tipifarnib is an orally bioavailable, nonpeptidomimetic methylquinolone FTI that has exhibited clinical activity in patients with myeloid malignancies including elderly adults with acute myelogenous leukemia (AML) who are not candidates for traditional cytotoxic chemotherapy, patients with high-risk myelodysplasia, myeloproliferative disorders, and imatinibresistant chronic myelogenous leukemia. Because of its relatively low toxicity profile, tipifarnib provides an important alternative to traditional cytotoxic approaches for elderly patients who are not likely to tolerate or even benefit from aggressive chemotherapy. In this review, we will focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as induction therapy for elderly adults with poor-risk AML and as maintenance therapy following achievement of first complete remission following induction and consolidation therapies for poor-risk AML. As with all other malignancies, the optimal approach is likely to lie in rational combinations of tipifarnib with cytotoxic, biologic and/or immunomodulatory agents with non-cross-resistant mechanisms of action. Gene expression profiling has identified networks of differentially expressed genes and gene combinations capable of predicting response to single agent tipifarnib. The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and in patients with AMl and other hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)491-500
Number of pages10
JournalBiologics: Targets and Therapy
Volume2
Issue number3
DOIs
StatePublished - 2008

Keywords

  • Acute myelogenous leukemia (AML)
  • Farnesylation
  • Farnesyltransferase inhibitor
  • Gene expression
  • Signal transduction
  • Tipifarnib

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this